Aktienanalyse zu Celularity Inc (CELU)CELUCelularity Inc

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Its IMPACT manufacturing platform is a fully integrated process designed to optimize the speed of the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing and control (CMC), advanced cell manufacturing and cryopreservation. It also provides contract manufacturing and development services to third parties. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Celularity Inc is a good buy right now due to its recent price increase of 97.49% over the past five days and a current RSI of 67.467, indicating strong momentum. The partnership with MuseCell could potentially generate over $300 million in revenue over the next five years, which is a significant positive catalyst. However, the company faces risks due to its Nasdaq compliance issues, particularly the need to submit a compliance plan by September 4, 2026, which could impact its stock performance.